

Increasing Investments In Research Fuels Growth Of The Alpha Mannosidosis Market

The Business Research Company's Alpha Mannosidosis Global Market Report 2021: COVID-19 Growth And Change

LONDON, GREATER LONDON, UK, May 31, 2021 /EINPresswire.com/ --

Increasing investments in research is expected to contribute to the growth of the [alpha mannosidosis market](#) in the forecast period. Currently, in the alpha mannosidosis market, only one company has therapies for the rare genetic disease. However, several firms


have products in the clinical stages, which will boost market demand in the forecast period. For instance, in 2020, the EU clinical trials database lists 39,219 clinical trials with a EudraCT protocol, 6,426 of which are clinical trials involving subjects under the age of 18. Therefore, the increasing investment in research fuels the growth of the alpha mannosidosis market.

The alpha mannosidosis market consists of sales of therapies for alpha mannosidosis (organizations, sole traders and partnerships) that provides treatment for alpha mannosidosis, which is a lysosomal storage disorder. Lysosomes are particles bound in membranes within cells that function as the primary digestive units. Alpha-mannosidosis is a rare genetic inherited condition that affects the organs and tissues of the person suffering from the disease. The treatment therapy focuses on detecting and preventing polysaccharide accumulations within mutant cells, which can cause harm to tissue, organs, and eventually death. Polysaccharides are defined as larger molecules composed of several linked sugar molecules.

Read More On The Global Alpha Mannosidosis Market Report:

<https://www.thebusinessresearchcompany.com/report/alpha-mannosidosis-global-market-report>

The global alpha mannosidosis market size is expected to grow from \$7.50 million in 2020 to \$8.89 million in 2021 at a compound annual growth rate (CAGR) of 18.6%. The growth is mainly due to increasing prevalence of alpha mannosidosis, use of orphan drugs, fee reductions and tax



credits, increasing investment in the rare disease treatment and advancements in treatment drugs. The alpha mannosidosis market is expected to reach \$17.91 million in 2025 at a CAGR of 19.1%.

North America was the largest region in the alpha mannosidosis market in 2020. Asia Pacific is expected to be the fastest growing region in the forecast period. The regions covered in the alpha mannosidosis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Major players in the alpha mannosidosis market are Chiesi Farmaceutici S.p.A., Nuo Therapeutics, and Zymenex.

The global alpha mannosidosis market research report is segmented -

1) By Therapy Type: Bone Marrow Transplant (BMT), Enzyme Replacement Therapy (ERT), Peripheral Blood Stem Cell Transplantation (PBSCT), Gene Therapy

2) By Indication: Type I, Type II, Type III

3) By End-User: Hospitals, Specialty Clinics.

[Alpha Mannosidosis Global Market Report 2021](#): COVID-19 Growth And Change is one of a series of new reports from The Business Research Company that provides alpha mannosidosis global market overview, forecast alpha mannosidosis global market size and growth for the whole market, alpha mannosidosis global market segments, and geographies, alpha mannosidosis global market trends, alpha mannosidosis global market drivers, restraints, leading competitors' revenues, profiles, and market shares.

Request For A Sample Of The Global Alpha Mannosidosis Market Report:

<https://www.thebusinessresearchcompany.com/sample.aspx?id=4093&type=smp>

Here Is A List Of Similar Reports By The Business Research Company:

Transplant Diagnostics Global Market Report 2021: COVID-19 Growth And Change To 2030

<https://www.thebusinessresearchcompany.com/report/transplant-diagnostics-global-market-report>

Oral Biologics And Biosimilars Market - By Therapeutic Mechanism (Tumor Necrosis Factor-Alpha Inhibitors, Lymphocyte Modulators, Interleukin Inhibitors, GPCR (insulin, growth hormone, parathyroid hormone) Modulators, Immunostimulants, Others), By Disease (Diabetes, Arthritis & Chron `s Disease, Cancer, Infectious Diseases, Other Autoimmune Diseases, Others Diseases), By Molecule Type (Vaccines, Proteins & Peptides, Monoclonal Antibodies, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), And By Region, Opportunities And Strategies - Global Forecast To 2030

<https://www.thebusinessresearchcompany.com/report/oral-biologics-and-biosimilars-market>

Cell and Gene Therapy Global Market Report 2021: COVID-19 Growth And Change To 2030
<https://www.thebusinessresearchcompany.com/report/cell-and-gene-therapy-global-market-report-2020-30-covid-19-growth-and-change>

Pharmaceuticals Market - By Type (Pharmaceutical Drugs, Biologics), By Type Of Pharmaceutical Drugs (Cardiovascular Drugs, Dermatology Drugs, Gastrointestinal Drugs, Genito-Urinary Drugs, Hematology Drugs, Anti-Infective Drugs, Metabolic Disorder Drugs, Musculoskeletal Disorder Drugs, Central Nervous System Drugs, Oncology Drugs, Ophthalmology Drugs, Respiratory Diseases Drugs), By Type Of Biologics Drugs (Monoclonal Antibodies (MAbs), Therapeutic Proteins, Vaccines), And By Region, Opportunities And Strategies – Global Forecast To 2030
<https://www.thebusinessresearchcompany.com/report/pharmaceuticals-market>

Interested to know more about [The Business Research Company?](#)

Read more about us at <https://www.thebusinessresearchcompany.com/about-the-business-research-company.aspx>

The Business Research Company is a market research and intelligence firm that excels in company, market, and consumer research. It has over 200 research professionals at its offices in India, the UK and the US, as well a network of trained researchers globally. It has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services and technology.

Call us now for personal assistance with your purchase:

Europe: +44 207 1930 708

Asia: +91 88972 63534

Americas: +1 315 623 0293

Oliver Guirdham

The Business Research Company

+44 20 7193 0708

info@tbrc.info

Visit us on social media:

[Facebook](#)

[Twitter](#)

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/542556365>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

